Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laurus LabsBOM:540222 -1.02%61 PB Ratio is 18.75 as of Aug. 13, 2026, which is 228% above its 10-year median of 5.72. GuruFocus rates BOM:540222 with a GF Score™ of 61/100 and a GF Value™ of ₹839.18 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 920 Drug Manufacturers companies, Laurus Labs ranks worse than 95.98% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-13), Laurus Labs's share price is ₹1841.05. Laurus Labs's Book Value per Share for the quarter that ended in Jun. 2026 was ₹98.18. Hence, Laurus Labs's PB Ratio of today is 18.75.
Warning Sign:
Laurus Labs Ltd stock PB Ratio (=18.89) is close to 10-year high of 18.89.
The historical rank and industry rank for Laurus Labs's PB Ratio or its related term are showing as below:
BOM:540222'
s PB Ratio Range Over the Past 10 Years
Min: 2.07 Med: 5.72 Max: 19
Current: 18.75
During the past 13 years, Laurus Labs's highest PB Ratio was 19.00. The lowest was 2.07. And the median was 5.72.
BOM:540222's PB Ratio is ranked worse than 95.98% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs BOM:540222: 18.75
During the past 12 months, Laurus Labs's average Book Value Per Share Growth Rate was 18.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 18.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Laurus Labs was 51.30% per year. The lowest was 9.40% per year. And the median was 19.55% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Laurus Labs PB Ratio Related Terms
Laurus Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for Laurus Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Laurus Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Laurus Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Laurus Labs (BOM:540222) has a PB Ratio of 18.75 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Laurus Labs and its competitors. This is 228% above median its historical median of 5.72. Over the past decade, Laurus Labs' PB Ratio has ranged from 2.07 to 19.00. According to the industry distribution chart, Laurus Labs ranks #883 out of 920 companies in the Drug Manufacturers industry, placing it in the top 96%.
Is Laurus Labs' PB Ratio too high?
Laurus Labs' current PB Ratio of 18.75 is 228% above median its 10-year median of 5.72. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 19.00. The Drug Manufacturers industry median PB Ratio is 1.99. Laurus Labs' value of 18.75 is 842.2% above this industry median. Based on the distribution chart, Laurus Labs ranks #883 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Laurus Labs has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #883 out of 920 companies for PB Ratio. This places Laurus Labs in the lower half of its industry. The industry median PB Ratio is 1.99. Laurus Labs' value of 18.75 is 842.2% above this benchmark. Historically, Laurus Labs' own PB Ratio has ranged from 2.07 to 19.00 over the past decade. While the company's 10-year median is 5.72 vs. the industry median of 1.99, Laurus Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.99, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laurus Labs's current PB Ratio of 18.75 is 842.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Laurus Labs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current PB Ratio is 18.75, which is 228% above median its own 10-year median of 5.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹839.18, compared to a current price of ₹1,841.05 — trading 119.4% above its estimated fair value. The current PB Ratio is 18.75, which is 228% above median its 10-year median of 5.72 and 842.2% above the Drug Manufacturers industry median of 1.99. Laurus Labs' overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current PB Ratio is 18.75 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,841.05 is trading 119.4% above its estimated GF Value™ of ₹839.18.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
PB Ratio: 18.75 (228% above median its 10-year median of 5.72)
GF Value™: ₹839.18 vs. price of ₹1,841.05 (119.4% above fair value)
Industry Position: 842.2% above the Drug Manufacturers median (#883 of 920)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
61GF Score
Get the complete analysis for BOM:540222
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
